Retail Press Releases
SEE OTHER BRANDS

News on retail in the world

Retail Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Retail Press Releases.

Press releases published on July 22, 2025

Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors

Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors

MEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Morphoceuticals Inc., a TechBio company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of industry veteran Roger Pomerantz, MD, as Chairman …

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July …

Enthusiast Gaming’s U.GG Launches Support for Rematch, Surpasses 100,000 Player Profiles in First Two Weeks

Enthusiast Gaming’s U.GG Launches Support for Rematch, Surpasses 100,000 Player Profiles in First Two Weeks

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a digital publisher focused on building tools, platforms, and experiences for gamers, is pleased to announce that U.GG, its …

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) …

Goodfood Reports Third Quarter of 2025 Results with Net Sales of $31 million, Gross Profit of $14 million and Adjusted EBITDA¹ of $3 million

Goodfood Reports Third Quarter of 2025 Results with Net Sales of $31 million, Gross Profit of $14 million and Adjusted EBITDA¹ of $3 million

Net sales were $31 million, with gross margin2 reaching 44.3% for a gross profit of $14 million for this quarter Net income of $0.1 million, adjusted EBITDA margin1 of 8.6% and adjusted EBITDA1 of $3 million for the quarter Cash flows provided by operating …

Goodfood annonce ses résultats du troisième trimestre de 2025 avec des ventes nettes de 31 millions de dollars, un bénéfice brut de 14 millions de dollars et un BAIIA ajusté¹ de 3 millions de dollars

Goodfood annonce ses résultats du troisième trimestre de 2025 avec des ventes nettes de 31 millions de dollars, un bénéfice brut de 14 millions de dollars et un BAIIA ajusté¹ de 3 millions de dollars

Les ventes nettes se sont élevées à 31 millions de dollars, avec une marge brute2 atteignant 44,3 % pour un bénéfice brut de 14 millions de dollars pour le trimestre Bénéfice net de 0,1 million de dollars, marge du BAIIA ajusté1 de 8,6 % et BAIIA ajusté1 …

Canned Tuna Market Size Expected to Reach USD 45.17 Bn by 2034 Amid Rising Demand for Protein-Rich, Health-Conscious Foods

Canned Tuna Market Size Expected to Reach USD 45.17 Bn by 2034 Amid Rising Demand for Protein-Rich, Health-Conscious Foods

Ottawa, July 22, 2025 (GLOBE NEWSWIRE) -- In terms of revenue, the worldwide canned tuna market surpassed USD 33.41 billion in 2024 and is projected to rise from USD 34.58 billion in 2025 to 42.82 billion by 2032. With the surge in health-conscious eating, …

Eviden sets the stage for AtLaS, the European Defence Fund challenge on Human Language Technology processing

Eviden sets the stage for AtLaS, the European Defence Fund challenge on Human Language Technology processing

Press Release Eviden sets the stage for AtLaS, the European Defence Fund challenge on Human Language Technology processing Selected by the European Commission, Eviden will provide a platform to integrate the applications and its own innovative human …

Eviden conçoit pour le Fonds européen de la défense, la plateforme technologique du défi AtLaS sur le traitement des technologies du langage humain

Eviden conçoit pour le Fonds européen de la défense, la plateforme technologique du défi AtLaS sur le traitement des technologies du langage humain

Communiqué de presse Eviden conçoit pour le Fonds européen de la défense, la plateforme technologique du défi AtLaS sur le traitement des technologies du langage humain Sélectionnée par la Commission européenne, Eviden fournira une plateforme d’intégration …

Telix Reports $204M Revenue, Up 63% YOY

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All …

New research reveals majority of sports viewers face challenges watching streamed sports

New research reveals majority of sports viewers face challenges watching streamed sports

More households are opting to only have an OTT subscription, scrapping pay TV 40% of sports viewers exclusively watch sports via streaming services Pure play streaming services account for nearly a quarter of the NFL’s broadcast revenue WILMINGTON, Del., …

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly …

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions